Pathology: Classification and Immunoprofile

Abstract

The classification of neuroendocrine neoplasms (NENs) has been evolving steadily over the last decades. Important prognostic factors of NENs are their proliferative activity and presence/absence of necrosis. These factors are reported in NENs of all body sites; however, the terminology as well as the exact rules of classification differ according to the location of the primary tumor. Only in gastroenteropancreatic (GEP) NENs a formal grading is performed. This grading is based on proliferation assessed by the mitotic count and/or Ki-67 proliferation index. In the lung, NEN grading is an intrinsic part of the tumor designation with typical carcinoids corresponding to neuroendocrine tumor (NET) G1 and atypical carcinoids to NET G2; however, the presence or absence of necrotic foci is as important as proliferation for the differentiation between typical and atypical carcinoids. Immunohistochemical markers can be used to demonstrate neuroendocrine differentiation. Synaptophysin and chromogranin A are, to date, the most reliable and most commonly used for this purpose. Beyond this, other markers can be helpful, for example in the situation of a NET metastasis of unknown primary, where a hormonal profile or a panel of transcription factors can give hints to the primary site. Many immunohistochemical markers have been shown to correlate with prognosis but are not used in clinical practice, for example cytokeratin 19 and KIT expression in pancreatic NETs. There is no predictive biomarker in use, with the exception of somatostatin receptor (SSTR) 2 expression for predicting the amenability of a tumor to in vivo SSTR targeting for imaging or therapy. Classification of Neuroendocrine Neoplasms in the Gastroenteropancreatic SystemThe histological diagnosis of neuroendocrine neoplasms (NENs) is based on morphological criteria and is confirmed by immunohistochemical staining. NENs are subdivided into well-differentiated tumors and poorly differentiated carcinomas, according to their histomorphologic appearance.

Extremely Long Survival under Combined Immunotherapy in a Metastatic Functional Neuroendocrine Neoplasia Patient

“…Immunohistochemical staining is essential for the detection of the neuroendocrine markers that are usually expressed by these tumors, including synaptophysin, chromogranin A and others, if clinically relevant [16, 17]. Treatment and prognosis depends on the size, stage, grade, resectability, and distant metastasis.…”